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Immunogenicity of Varicella-zoster virus glycoproteins gE, gB, gH, and gL expressed by recombinant vaccinia viruses (V V)
separately or simultaneously was determined in mice and guinea pigs by ELISA, Western blotting, radioimmunoprecipitation,
plaque reduction assay, and skin test. Single V V-gE and V V-gB recombinants and double V V-gH/gL recombinant elicited
specific antibodies with VZV neutralizing activity in mice. Co-expression of gE and gB by one recombinant V V resulted in an
increased antibody response in comparison with immunization with single recombinants or their mixtures. Unlike anti-gB and
anti-gH/gL antibodies, the gE-specific antibodies had no virus neutralizing activity in absence of complement, and when used
alone, they even caused considerable increase of VZV infectious units. Moreover, immune sera containing anti-gE antibodies
antagonized complement independent virus-neutralizing activity of anti-gB- and anti-gH/gL-positive sera. The ability to induce
delayed hypersensitivity reaction to VZV antigens was observed after immunization of guinea pigs with gE- and/or
gB-expressing V Vs. © 2001 Academic PressKey Words: varicella-zoster virus; herpesviruses; glycoproteins; vaccinia virus; vaccine; antibodies; cellular imunity; virus
neutralization; immunization.INTRODUCTION
Varicella-zoster virus (VZV) is responsible for chicken-
pox and shingles. The host reactivity to VZV involves both
humoral and cell-mediated immune responses (for re-
view, see Arvin, 1995). The major viral antigens of VZV
are the glycoproteins (gps), gE, gB, gH, and gL, which are
structural components of the virion envelope. Glycopro-
tein gE (M r 90–98 kDa) is the most abundant viral gp in
VZV-infected cells (Montalvo and Grose, 1985). This gly-
coprotein is highly modified by both N- and O-linked
sugars, sialiation, myristylation, palmitylation and sul-
phation, as well as by serine/threonine and tyrosine
phosphorylation (Grose, 1990; Harper and Kangro, 1990;
Namazue et al., 1989). In infected cells, VZV gE forms a
noncovalently linked complex with VZV gI (Yao et al.,
1993). Owing to two targeting signals (Alconada et al.,
1996; Zhu et al., 1996), gE is targeted to trans-Golgi
network (TGN). The gE molecule binds Fc fragment of
IgG. Usually, antibodies against gE are able to neutralize
VZV infection in vitro in the presence of complement only
(Grose and Litwin, 1988; Ludvı´kova´ et al., 1991); however,
complement-independent neutralizing monoclonal gE
antibodies have been also prepared (Wu and Forghani,
1997). The second most strongly immunogenic glycopro-
tein of VZV, gB, is a heterodimer of two polypeptide
chains (M r 66 and 65 kDa) that are linked by disulphide1 To whom reprint requests should be addressed. Fax: 1420 2
1977392. E-mail: sarkan@uhkt.cz.
211bonds. Molecule of gB contains both N- and O-linked
sugars, and it is sialiated, sulphated, and palmitylated
(Grose, 1990). The gB was found to bind to cell-surface
heparan sulphate proteoglycans (Jacquet et al., 1998).
Glycoprotein gB elicits complement-independent virus-
neutralizing antibodies (Edson et al., 1985a,b). The gB-
specific antibodies inhibit VZV-induced cell-to-cell fusion
in infected monolayers (Montalvo and Grose, 1987). The
third most abundant VZV glycoprotein, gH, is associated
with another viral glycoprotein, gL, with chaperone func-
tion (Forghani et al., 1994), and this complex is trans-
ported to the cell surface (Duus et al., 1995). The gH:gL
complex is responsible for viral entry, egress, cell fusion,
and cell-to-cell spread of the VZV in cultured cells. Gly-
coprotein gH induces complement-independent neutral-
izing antibodies. Two other glycoproteins, gC and gI,
induce low-level immune responses (Huang et al., 1992).
Also some non-glycosylated viral proteins like IE62 or
thymidine kinase are significant targets of host-immune
responses. Although cell-mediated immune response is
more important for limiting the spread of virus and clear-
ing infection (Arvin, 1995), antibodies also substantially
interfere with VZV replication in vivo as is evident from
reduction of severity of varicella after administration of
high-titer VZV immunoglobulin (Zaia et al., 1983). The
exact role of particular viral antigens in induction of
immune status is not well understood. It has been shown
that antibody responses to gE and gB after natural infec-
tion and after vaccination with OKA vaccine is highly
variable from one individual to another; however, these
0042-6822/01 $35.00
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212 KUTINOVA´ ET AL.two glycoproteins are predominant among other viral
antigens in respect to induction of VZV-neutralizing anti-
bodies (Haumont et al., 1997).
We have recently shown that VZV glycoproteins gE
and gH:gL expressed by recombinant vaccinia virus
(Ludvı´kova´ et al., 1991; Neˇmecˇkova´ et al., 1996) elicit
ntibodies with virus-neutralizing activity in mice. The
oals adressed in this paper were to better characterize
he main immunogennic VZV glycoproteins that are sup-
osed to be included into a subunit vaccine against VZV,
o determine the contribution of the particular glycopro-
eins to humoral and cellular immune responses, and to
valuate the influence of coexpression of the glycopro-
eins. For this purpose, we prepared a set of single and
TABLE 1
V V-VZV Recombinants Used in Immunization Experiments
Recombinant V V Promoter
Insertion site in V V genome
TK gene HA gene
V V-gE 7.5 gE —
V V-gB 11k gB —
V V-gE/gB 7.5/11k gB gE
V V-gH 7.5 gH —
V V-gL 11k gL —
V V-gH/gL 7.5/11k gH gL
T
Antibody Response of Mice Inoculated
Group No.
Dose of virus inoculated
i.p. into mice
E
A
VZV antigenb
1 V V-gE 1.106 f 1.00 6 0.19g
2 V V-gB 1.106 0.54 6 0.14
3 V V-gB 3.106 0.65 6 0.21
4 V V-gB 10.106 0.60 6 0.32
5 V V-gB 1.106 1 V V-gE 1.106 1.17 6 0.25
6 V V-gB 3.106 1 V V-gE 1.106 1.30 6 0.19
7 V V-gB 10.106 1 V V-gE 1.106 0.96 6 0.28
8 V V-gE/gB 1.106 1.42 6 0.33
9 V V-gB 1.106 1 V V-gL 1.106 0.50 6 0.08
10 V V-gB 3.106 1 V V-gL 1.106 0.75 6 0.13
11 V V-gB 10.106 1 V V-gL 1.106 0.72 6 0.25
12 V V-gL 10.106 0.06 6 0.13
a Antigen prepared from VZV-infected cells was used in all ELISA te
b Non-absorbed individual mouse sera.
c Pooled sera were absorbed with antigen prepared from V V-gB-infe
d Pooled sera were absorbed with antigen prepared from V V-gE-infe
e Intensity of staining of gE 98-kDa band and gB 120-kDa band was
f Amount of recombinant virus administered (PFU).
g Standard deviation.
h Reciprocal of highest serum dilution that neutralized $50% of VZV plaqueouble VV recombinants expressing four VZV genes (gE,
B, gH, and gL) and used them for immunization of mice
nd guinea pigs. Humoral and cell-mediated immune
esponses to VZV antigens were determined.
RESULTS
ntibody response of mice inoculated with gE- and
B-expressing recombinant VVs
To evaluate the immunogenicity of VV-VZV recombi-
ants, the antibody responses of mice inoculated with
arious doses of different recombinants (Table 1) and of
heir mixtures were analyzed. Results of the examination
f sera of mice after administration of VV-expressing gE
nd gB are shown in the upper part of Table 2. The
esults obtained by ELISA and WB indicate that both
lycoproteins are relatively good immunogens in mice
ince the administration of 1.106 PFU (Groups 1 and 2) of
ither VV-gE or VV-gB induced specific antibodies. As
bserved for the VV-gB recombinant, the amount of an-
ibodies formed depended on the dose of the recombi-
ant virus administered but only within a certain range of
oses (Groups 2–4). The data on gE and gB antibodies
onitored by ELISA and WB were in good agreement. To
est the immunogenicity, mixtures of the two recombi-
ants containing one dose of VV-gE (1.106 PFU) and
ncreasing doses of VV-gB (1.106, 3.106, or 10.106 PFU)
were co-injected (Groups 5–7). To further determine the
combinant V Vs Expressing gE and gB
s. 492 nm]
a WB[OD]
Neutralization
titer of sera
ies to Antibodies to Complement
gEc gBd gEe gBe 2 1
0.90 0.09 114 0 ,4h 8
0.07 0.56 0 9 4 8
0.06 0.69 0 38 128 512
0.21 0.72 0 48 128 256
0.83 0.60 75 4 ,4 16
0.71 0.78 32 11 16 128
0.54 0.74 11 11 8 256
1.09 0.73 130 21 4 512
— — 0 13 8 32
— — 0 44 128 512
— — 0 62 128 512
— — 0 0 ,4 ,4
V-1 cells.
V-1 cells.
ined densitometrically.ABLE 2
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213IMMUNIZATION WITH VZV GLYCOPROTEINSeffect of co-administered virus, VV-gE was replaced by
the control VV-gL virus (Groups 9–11). VV-gL was chosen
because it does not induce VZV-specific antibodies re-
active in the tests used (Group 12). As evidenced by both
ELISA and WB, the presence of increasing amount of the
second VV in the mixture reduced the antibody response
to the gE antigen. Inoculation of a mixture of VV-gE and
VV-gB recombinants and in particular the double VV-
gE/gB recombinant induced higher levels of antibodies
against the complex VZV antigen than did any single VV
recombinant tested. The VZV-neutralizing activity of sera
from all groups immunized with gE- and/or gB-express-
ing VVs was measured using plaque reduction test. In
agreement with previous reports, sera of mice immu-
nized with VV-gE neutralized VZV only in the presence of
complement (Group 1). On the other hand, gB-specific
virus-neutralizing antibodies were detected both in the
presence and absence of complement, and the magni-
tude of neutralization titers was in good agreement with
the values found by the other tests used (Groups 2–4).
The highest virus-neutralizing activity was found in sera
of mice immunized with the double VV-gE/gB recombi-
nant (Group 8) or high doses of the VV-gB recombinant in
the presence of complement (Groups 3, 10, and 11).
Surprisingly, administration of VV-gE in mixtures with
various amounts of V V-gB, or immunization with recom-
binant VV-gE/gB, resulted in decreased levels of antibod-
ies capable of neutralizing VZV in the absence of com-
plement (Groups 5–8), although the gB-specific antibody
levels present in such sera were rather high (e.g. in
Group 8). A low complement-independent virus-neutral-
izing capacity of sera was not observed if VV-gL was
used instead of VV-gE in the mixture (Groups 9–11).
Antibody response in mice inoculated with gH- and/or
gL-expressing recombinant VVs
Antibodies against gH were determined using the ra-
dioimmunoprecipitation assay since they could not be
T
Antibody Response of Mice Immunized with
Group No.
Dose of virus inoculated
i.p. into mice
1 V V-gL 1.107
2 V V-gH 1.107
3 V V-gH 1.107 1 V V-gL 1.107
4 V V-gH/gL 1.107
5 V V-gH/gL 1.106
8 V V-gH/gL 1.106 1 V V-gE/gB 1.106
9 V V-gH/gL 1.106 1 V V-gE/gB 3.106
10 V V-gH/gL 1.106 1 V V-gE/gB 10.106detected by either ELISA or WB. Bands corresponding to
glycoproteins gH gL and pre-gH were measured densi-
s
5tometrically, and OD values of their peak areas are
shown in Table 3. We did not observe any specific band
precipitated by sera of mice inoculated with the VV-gL
(Group 1) or VV-gH (Group 2) single recombinants, given
alone or together (Group 3), at a dose of 1.107. As for the
V-gH/gL double recombinant, a dose of 1.107 PFU
(Group 4) induced slightly higher levels of anti-gH and
anti-gL antibodies than did a dose of 1.106 (Group 5). The
sera precipitated both a fully processed 118-kDa form of
gH combined with a 19-kDa form of gL and a premature
97-kDa form of gH. If the mice were immunized with
mixtures of both double recombinants VV-gH/gL and
VV-gE/gB, we observed that increasing the dose of latter
virus in the mixture resulted in decrease of the antibod-
ies elicited by the former virus (Groups 8–10). This is an
observation similar to that seen after immunization with
the mixtures of VV-gE and gB (Table 2).
The virus-neutralizing capacities of sera of mice inoc-
ulated with the single VV-gL or VV-gH recombinant, with
their mixtures, or with the double recombinant VV-gH/gL
were also compared. Administration of single recombi-
nants or their mixtures at a dose of 1.107 PFU did not elicit
virus neutralizing antibodies of a titer $4 (not shown).
The presence of high titers of virus-neutralizing antibod-
ies after immunization with 1.106 PFU of double recombi-
ant VV-gH/gL (Table 4, Group 4) confirmed that the
enes coding for gH and gL must be expressed simul-
aneously in the same cell to process the gH:gL immuno-
en properly. We compared the efficacy of the adminis-
ration of both double recombinants VV-gE/gB and VV-
H/gL mixed at various ratios (Table 4). The
imultaneous inoculation of both viruses (Groups 1–3)
id not result in an increase of virus neutralizing antibody
iters in comparison with the inoculation of one recom-
inant only (Groups 4–7). Raising the VV-gE/gB virus
ose in mixtures (Groups 2 and 3) resulted in a reduction
f complement-independent virus-neutralizing antibod-
es. A similar negative effect of anti-gE antibodies was
pressing gH and/or gL as Detected by RIPA
Peak area of gp precipitated [OD]
H (118 kDa) gL (19 kDa) pre-gH (97 kDa)
0 0 0
0 0 0
0 0 0
8204 1893 2450
7549 1426 2494
4612 1151 1735
2627 530 897
1514 0 390ABLE 3
V Vs Ex
geen also in Experiment 1 shown in Table 2 (Groups
–7). This decrease of titers either could be the result of
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214 KUTINOVA´ ET AL.a negative influence of unequal doses of the two viruses
in the mixtures as recently reported (Kutinova´ et al., 1999)
or could be due to some specific influence of anti gE
antibodies on the virus. To elucidate this effect, we
tested the influence of anti-gE-positive sera in the ab-
sence of complement in more detail.
Enhancement of VZV infection in vitro by anti-gE-
positive sera in the absence of complement
When anti-VV-gE sera were titrated in the absence of
complement, we repeatedly observed an increase in the
VZV plaque count in comparison with untreated virus.
This effect was exhibited by the same serum dilutions
which were active in VZV neutralization in the presence
of complement (Fig. 1A). Relative plaque numbers were
expressed as percentages of plaque counts in serum-
free controls. To see whether gE-specific antibodies
could influence sera containing gB- or gH/gL-specific
antibodies, we tested the effect of various serum mix-
tures. The effect of anti-gE antibody presence on the
activity of complement-independent anti-gB antibodies is
shown in Fig. 1B. Both sera and their mixture neutralized
VZV in the presence of complement. Addition of anti-gE
antibodies to various dilutions of anti-gB serum subse-
quently reduced the virus-neutralizing activity of anti-gB
antibodies in the absence of complement. The continu-
ous increase of the plaque number was associated with
the decreasing concentration of anti-B antibody in mix-
tures. Similarly, in the absence of complement anti-gE,
immune sera inhibited the neutralization activity of both
concentrations (1:16, 1:32) of VV-gH/gL serum used, as is
shown in Fig. 1C. This enhancement was dependent on
the amount of anti-gH/gL-neutralizing antibody. The ef-
fect was anti-gE specific, and it was not observed for any
other sera of mice immunized with recombinants such as
TABLE 4
In Vitro Neutralization of VZV with Sera of Mice Immunized with the
Double Recombinant V Vs Expressing gE/gB and/or gH/gL
Group No.
Dose of virus inoculated
i.p. into mice
Neutralization
titer of sera
(Complement)
2 1
1 V V-gH/gL 1.106 a 1 V V-gE/gB 1.106 128b 128
2 V V-gH/gL 1.106 1 V V-gE/gB 3.106 64 128
3 V V-gH/gL 1.106 1 V V-gE/gB 10.106 16 256
4 V V-gH/gL 1.106 128 128
5 V V-gE/gB 1.106 ,4 128
6 V V-gE/gB 3.106 8 256
7 V V-gE/gB 10.106 16 256
a,b For explanations, see Table 2.VV-gB, VV-gH, VV-gL, V V-preS2-S or nonrecombinant
VV TK2.utaneous reaction to VZV antigens
Cellular immune responses of guinea pigs immunized
ith recombinant VV were tested by the skin test. Cuta-
eous reactions were measured 48 h after intradermal
noculation of test antigen. The results of two immuniza-
ion experiments are shown in Table 5. In the first exper-
ment, guinea pigs were infected with seven different
ecombinant VVs, a mixture of two double recombinants,
xtracellular VZV-Oka, or with PBS. The table shows
ean cutaneous reaction values 6 standard deviation
SD). As compared with reactions after VV-preS2S inoc-
lation taken as a background negative control, weakly
ositive cutaneous reactions were induced in animals
mmunized with VV-gE or VV-gB. The differences from
egative control were not statistically significant from
hat could be caused by great variability of animal
esponses. However, we observed several times that
ositive reactions to VZV antigen were accompanied by
ore intensive colouring of erythema (not shown). In
nimals immunized with VV-gE/gB or with a mixture of
V-gE/gB 1 VV-gH/gL, the mean values of skin reaction
size differed from the control group significantly (P 5
0.029 and P 5 0.009, respectively). The response in
animals immunized with VZV-Oka also showed a signif-
icant difference (P 5 0.021). No positive cutaneous
reaction was observed in controls injected with PBS only
or in animals infected with the single recombinants VV-
gH, VV-gL or, surprisingly, with the double recombinant
VV-gH/gL.
Sera of all animals were tested for the presence of
anti-VZV and anti-V V antibodies 5 weeks after immu-
nization. Inoculation of recombinant V Vs elicited anti-
V V responses in all animals. All sera also contained
VZV-neutralizing antibodies. Since the sera of groups
inoculated with PBS and V V-preS2S displayed VZV-
neutralizing activity at titers of 8–16, it is obvious that
at least a portion of these antibodies was produced in
response to the administration of skin-test antigens. A
finding of relatively high neutralization activity in sera
from animals immunized with V V-gE/gB, V V-gE, or
V V-gB confirmed an immunizing capability of V V-ex-
pressed gE and gB in guinea pigs. Unlike mice, guinea
pigs were apparently less capable of responding to
V V-expressed gH/gL by production of VZV-neutralizing
antibodies, and this might have been associated with
their failure to develop skin reactivity. To investigate
this point further and to confirm the most important
data from Experiment I, another experiment (Table 5,
Experiment II) was carried out in which V VgE/gB and
V VgH/gL recombinants were used for immunization
and the skin test was only performed in a portion of the
animals. We found no cutaneous reaction and no an-
tibodies reacting with VZV in neutralization test in
V V-gH/gL-inoculated animals, which were not boosted
by skin test antigen.
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215IMMUNIZATION WITH VZV GLYCOPROTEINSDISCUSSION
Immune response to particular glycoproteins following
nfection with VZV has been well documented (Weigle
FIG. 1. Enhancement of VZV plaque formation by immune sera of m
E-positive sera in the presence (-h-) and absence (-n -) of compleme
1.106 V V with the gE gene inserted into hemagglutinin of V V. The relat
counts in samples without serum. (B) Inhibition of complement-indepen
serum. One dilution (1:6) of anti-gE-positive serum (after immunizatio
serum. Virus neutralization activity was tested either in the presence (C
irus neutralization activity of anti-gH/gL-positive serum by anti-gE-po
-V V-gB, 3-V V-gH, 4-V V-gL, 5-V V-preS2-S, or 6-V V(TK2) diluted 1:6 wer
or the sera were used unmixed (no gH/gL). The last two bars (7-none
controls were assayed by the plaque reduction test in the absence ofnd Grose, 1984; Brunell et al., 1987; Dubey et al., 1988;
rvin et al., 1991; Haumont et al., 1997), but data onmmunogenicity of separately expressed VZV glycopro-
eins are less numerous (Vafai and Yang, 1991; Vafai,
993; Ludvı´kova´ et al., 1991; Lowry et al., 1992; Massaer
t al., 1993; Neˇmecˇkova´ et al., 1996). The results of the
ulated with V V-gE. (A) Plaque reduction and plaque enhancement by
ectively. The gE-positive sera were pooled from mice immunized with
bers of plaques in all three graphs represent percentages of plaque
irus neutralization activity of anti-gB-positive serum by anti-gE positive
V V-gE) was mixed with serial dilutions (1:8–1:512) of anti-gB-positive
bsence (C2) of complement. (C) Inhibition of complement-independent
serum but not by other sera. Sera of mice immunized with 1-V V-gE,
d with serum of mice immunized with V V-gH/gL, diluted, 1:16 or 1:32,
sent virus neutralization by unmixed anti-gH/gL. The mixed sera and
ement.ice inoc
nt, resp
ive num
dent v
n with
1) or a
sitive
e mixepresent series of experiments demonstrated that VV
recombinants expressing VZV gE, gB, or gH 1 gL glyco-
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216 KUTINOVA´ ET AL.protein genes were able to induce gE-, gB-, and gH-
specific antibodies, respectively, which displayed VZV-
neutralizing activity. Immunization with single recombi-
nants or with mixtures of single recombinants was, in all
combinations, less efficient than immunization with dou-
ble recombinants. It had already been known for some
time that to induce anti-gH neutralizing antibodies, gH
had to be expressed together with gL in the same cell;
doses lower than 2.107 PFU of VV-gH and VV-gL admin-
stered intraperitoneally did not induce virus-neutralizing
ntibodies in mice (Neˇmecˇkova´ et al., 1996). In the
present experiments, immunization with the VV-gE/gB
double recombinant resulted in much higher titers of
neutralization antibodies than those obtained with mix-
tures of the corresponding single recombinants. This
might have been a consequence of temporary interaction
between these two glycoproteins in the course of their
synthesis; it should be remembered that a complex,
heterooligomeric organization of glycoproteins has also
been found in other herpes viruses (Handler et al., 1996).
T
Cutaneous Reaction and Antibody Responses i
Virus N a
Skin reaction
Area [mm2]
Exp
V V-preS2S 3 20.0 6 24.9
V-gE/gB 3 57.7 6 8.5 0.
V-gH/gL 3 29.3 6 19.0 0.
V-gE/gB 1 V V-gH/gL 4 76.5 6 17.0 0.
V-gE 3 100.7 6 73.5 0.
V-gB 3 107.0 6 112.9 0.
V-gH 3 221.0 6 36.3 0.
V-gL 3 48.3 6 16.5 0.
ZV-Oka 3 176.3 6 98.0 0.
BS 4 0 6 0
Exp
V V-gE/gB 3 72.5 6 7.7 0.
V-gE/gBe 3 n.d.
V-gH/gL 4 8.0 6 8.0
V-gH/gLe 3 n.d.
Note. Area values are means 6 SD.
a Number of animals in group.
b In Experiment I, 60 mg of VZV antigen was intradermally injected 18 d
48 h after injection of antigen. Guinea pigs were bled out 5 weeks
determined in individual sera. VZV-neutralizing activity was measured
V V-VZV recombinants were compared with animals immunized with th
c Statistical significance was tested by the unpaired t test. * Indicate
riginally inoculated with V V-preS2S (in the 95% confidence interval).
d The animals in Experiment II were injected on the same time sch
Significance of the differences between cutanous reactions in V V-gE/g
e Skin test was not performed.However, our efforts to co-precipitate the gE/gB complex
24 h after infection with VV-gE/gB and crosslink it withdithio-bis(succinimidylpropionate) (Maresˇova´, results not
shown) have not been successful so far. Immunization
with mixtures of two double recombinants, VV-gE/gB and
VV-gH/gL, did not increase neutralization titers in postin-
fection sera. Cellular immune responses to glycopro-
teins gE, gB, and gH have been found in subjects with
acute and convalescent varicella (Arvin et al., 1986; Giller
et al., 1989) as well as in guinea pigs inoculated with the
Oka varicella vaccine (Sato et al., 1998). We observed
that glycoproteins gE and gB expressed by VV were able
to induce delayed-type hypersensitivity in guinea pigs
similarly as did immunization with extracellular VZV-OKA.
We could not find any significant skin reaction after
immunization with VV-gH/gL or VV-gH plus VV-gL, al-
though the presence of VV-specific antibodies in all
guinea pigs indicated that all animals were infected with
VV. Furthermore, the titers of anti-VV antibodies in ani-
mals inoculated with VV-gH/gL, VV-gB, or VV-gE/gB did
not differ markedly. It could be speculated that the
amount of gH/gL formed was sufficient to stimulate virus-
a Pigs Immunized with V V-VZV Recombinants
Antibodies[Abs 492 nm 6 SD]
Neutralization
titer of sera C1VZVag V Vag
t Ib
0.196 6 0.117 0.434 6 0.305 8
0.613 6 0.141 0.151 6 0.103 128
0.300 6 0.061 0.176 6 0.100 16
0.592 6 0.082 0.209 6 0.098 128
0.514 6 0.128 0.291 6 0.100 64
0.393 6 0.087 0.156 6 0.098 32
0.253 6 0.106 0.296 6 0.065 16
0.250 6 0.120 0.423 6 0.182 16
0.336 6 0.070 0.026 6 0.015 128
0.296 6 0.031 0.028 6 0.017 16
t IId
0.588 6 0.129 0.135 6 0.063 128
0.259 6 0.039 0.151 6 0.053 16
0.326 6 0.100 0.236 6 0.205 16
0.006 6 0.010 0.226 6 0.170 ,4
er administration of recombinant V V. Skin reaction area was measured
oculation of recombinant V V. VZV- and V V-specific antibodies were
led sera. Cutaneous reactions in animals inoculated with the various
reS2S recombinant.
e size of cutaneous reaction areas differed significantly from animals
and with the same doses of V V and VZV antigen as in Experiment I.
V V-gH/gL-injected animals was tested.ABLE 5
n Guine
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217IMMUNIZATION WITH VZV GLYCOPROTEINSpigs. It is likewise possible that the processing of these
two glycoproteins is less efficient in guinea pig than in
murine cells.
We also observed that when anti-gE-positive sera
were used in the absence of complement in neutraliza-
tion assays, the number of plaques increased. Antibody-
dependent enhancement (ADE) of virus infection in vitro
was described for several viruses, including human im-
munodeficiency virus type 1 (Homsy et al., 1990), influ-
enza virus (Ochiai et al., 1990), and respiratory syncytial
virus (Gimenez et al., 1989). ADE in these viruses can be
explained so that the exposed Fc portions of the anti-
bodies that are bound to virus particles bind to Fc receptors
on the surfaces of cells, thereby increasing the internaliza-
tion of the virus. This explains the mechanism of ADE in
macrophages or monocytes but is not likely for VZV infec-
tion of fibroblastoid LEP cells used in our study. We also
established that ADE was not due to an enhanced stability
of the gE-antibody-treated virus (results not shown).
At this writing, the nature of this observation is not
clear; however, it might be associated with some other
phenomena described recently. It has been observed by
Shiraki et al. (1997) that postinfection treatment of cells
with the gE:gI complex isolated by affinity chromatogra-
phy inhibited VZV plaque formation. The effect was dose
dependent and treatment of VZV-infected cells with 100
mg of purified glycoprotein reduced plaque number by
85%. VZV glycoproteins (Shiraki and Takahashi, 1982;
Montalvo and Grose, 1986), including gE (Maresˇova´ et
al., 2000), have been shown to be released from cells
infected with VZV or recombinant VV-gE, and therefore
the cell-free virus stocks prepared by sonication of VZV
infected cells may contain such inhibitory gE:gI com-
plexes. It follows that the actual titer of virus in different
stocks may depend on the concentration of infectious
virions and at the same time on the concentration of
inhibiting gE:gI complexes. Thus, the role of anti-gE an-
tibodies in ADE could be dependent on the binding of the
inhibitory antigens present in the preparations of cell-
free VZV used in the plaque reduction test. Formation of
antigen–antibody complexes could prevent the inhibitory
effect of free gE:gI on VZV infection and cause an in-
crease in the plaque count in vitro. The differences in the
content of free VZV glycoproteins in cell-free virus stocks
used in different laboratories for neutralization tests
might be responsible for different findings concerning
the capability of anti-gE antibody to neutralize VZV with-
out complement. The other mechanism operative may
involve the nature of gE antibodies used. Polyclonal
antibodies elicited by V V-gE recombinants may have a
higher affinity to soluble gE:gI complexes than monoclo-
nal antibodies used by other investigators.
Another possible mechanism of VZV infection en-
hancement by anti-gE could be based on the fact that gE
is internalized from the membrane of infected cells by
endocytosis (Olson and Grose, 1997). It has been ob-
S
Lserved that antibodies to gE of pseudorabies virus, an-
other alphaherpes virus, induced endocytosis and
caused bridging and capping of membrane glycopro-
teins on infected cells (Favoreel et al., 1999). It is possi-
le that increased ligand-induced endocytosis could re-
ult in a higher rate of infection.
Our results suggested that all three glycoproteins, gE,
B, and gH/gL, would be important components for a
uture subunit VZV vaccine. Although neither gE nor gB
equired co-synthesis of other glycoproteins so essen-
ially as gH required gL, the positive immunization effect
f VV-gE/gB suggested that interaction of viral glycopro-
eins could occur during their synthesis or processing
nd that the simultaneous synthesis of recombinant gly-
oproteins in the same cell could be worth considering
n designing a subunit vaccine.
MATERIALS AND METHODS
iruses and cells
All recombinant vaccinia viruses (VV) were prepared
rom clone P13 generated from smallpox Sevac VARIE
accine (strain Praha) (Kutinova´ et al., 1995). A list of
single and double recombinants containing VZV gene 37
(gH), gene 60 (gL), gene 31 (gB), or gene 68 (gE) inserted
in the VV thymidine kinase (TK) or hemagglutinin (HA)
genes is shown in Table 1. Expression of extrinsic genes
was controlled by VV early/late p7.5k or late 11k promot-
ers. Construction of single recombinant VVs expressing
VZV gE, designated VV-gE (Ludvı´kova´ et al., 1991) and
expressing gH and gL and designated VV-gH and VV-gL,
respectively (Neˇmecˇkova´ et al., 1996), were described
previously. Single recombinant VV-expressing gB and
double recombinants VV-gE/gB and VV-gH/gL were pre-
pared recently (Maresˇova´ et al., 2000). Electrophoretic
pattern of glycoproteins produced by recombinants used
in the present study have been shown in the recent
paper by Maresˇova´ et al. (2000). Glycoproteins gE, gB,
nd gH seemed to be produced in similar amounts. The
V-preS2-S-expressing middle envelope protein of Hep-
titis B virus was prepared from plasmid pM3 as de-
cribed previously (Kutinova´ et al., 1994). Thymidine-
inase-deficient VV denoted VV TK2 is a spontaneous
utant of P13 virus. Human-embryo diploid cells (LEP)
nd monkey-kidney cells (CV-1) were used for the growth
f recombinant viruses. All cells were cultivated in mod-
fied medium 199 (EPL) containing bovine serum growth-
ctive proteins but no complete serum (Michl, 1961). The
Vs used for immunization experiments were grown in
he chorioallantoic membranes of 11-day-old chicken
mbryos and partially purified by the modified method of
oklik (1962), (Kutinova´ et al., 1999). VZV (strain Zuzana)
as isolated in our laboratory from skin vesicle of a child
ith varicella. VZV-Oka was kindly provided by Dr. A.
auerbrei, Erfurt. Both VZV strains were propagated in
EP cells.
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218 KUTINOVA´ ET AL.Immunization of mice
Four-week-old outbred female mice, strain CD-1
(ICR)BR (Charles River), were injected intraperitoneally
with 0.5 ml PBS containing recombinant VV. Ten mice
were immunized in each group. Five weeks later the
mice were anesthetized with halothane (Narcotane, Le´-
civa, Praha) and bled out. Sera used in neutralization test
were inactivated at 56°C for 30 min.
Testing of antibodies
ELISA. Levels of VZV- and VV-specific antibodies in
individual mouse sera were determined by ELISA as
described previously (Ludvı´kova´ et al., 1991). For the
detection of specific gE and gB antibodies in mice im-
munized concurrently with these two VZV glycoproteins,
pooled sera diluted 1:10 were absorbed prior to testing.
The antigens for absorption were prepared from CV-1
cells infected with either VV-gB or VV-gE, and the ab-
sorption was performed as described previously (Neˇ-
mecˇkova´ et al., 1996).
Western blotting. Specific gE and gB antibodies were
quantified by Western blotting. In brief, LEP cell cultures
infected with VZV were harvested 2 days after infection
when the CPE had reached 90%. The cells, washed twice
with PBS, were scraped into PBS, centrifuged at 3000 g
and lysed in Laemmli buffer with 2-mercaptoethanol.
Samples were incubated at 95°C for 5 min and applied
on top of a 7.5% PAAG using a wide single-well comb.
The proteins separated were transferred to a nitrocellu-
lose membrane using the semidry electrophoretic
method. The membrane was stained with Ponceau S and
cut into 5-mm strips. The strips, preincubated with 10%
non-fat dry milk in PBS for 1 h, were incubated with
mixtures of the sera being tested, diluted 1:50, at 4°C
overnight. After washing (PBS, 0.2% Tween 20), the strips
were incubated with swine anti-IgG labeled with horse-
radish peroxidase, washed, and stained with diamino-
benzidine. The maxima of the 98-kDa band and the
120-kDa band corresponding to gE and the uncleaved gB
molecule, respectively, were scanned and quantified us-
ing the Scan PacK 3.0 programme (Biometra).
Radioimmunoprecipitation. Antibodies to gH and gL
proteins were determined using immunoprecipitation of
[35S]methionine- and cysteine-labeled VZV antigens pre-
ared by the procedure described previously (Neˇ-
ecˇkova´ et al., 1996). The extracts were prepared from
onolayers of CV-1 cells infected with VV-gH/gL or
V-gH recombinant or parental VV. Mixed sera from 10
ice, diluted 1:6, were absorbed with wt VV-infected
ells before testing as already described (Neˇmecˇkova´ et
l., 1996). Monoclonal antibody V3 (Sugano et al., 1991),
btained through the courtesy of T. Sugano, Tokyo, was
sed to detect processed gH in complex with gL and a
oster-patient serum was used to recognize premature
H. Autoradiograms were scanned and density of spe-ific bands (118 and 97 kDa for gH and 19 kDa for gL)
as quantified using the Scan PacK 3.0 programme
Biometra).
eutralization assay
The VZV-neutralizing capacity of sera was examined
y a plaque reduction test. The cell-free virus used in the
ssay was prepared similarly as was described by Ilobi
nd Martin (1989). In brief, VZV (strain Zuzana)-infected
EP cells exhibiting about 50–70% c.p.e. were scraped
nto E-MEM supplemented with 5% sucrose, 0.1% sodium
lutamate, and 10% thermoinactivated newborn calf se-
um. The resulting cell suspension was sonicated (Soni-
rep, MSE) at amplitude 14 mm for 30 s and centrifuged
t 950 g for 15 min. The supernatant fluid was used as
ell-free virus preparation, and it was stored in aliquots
t 265°C. In the neutralization test, the viruses were
iluted 1:20–1:30 to achieve 100 6 50 PFU in control
cultures. Several cell-free virus stocks were used in the
present study, but the data in each table or figure were
always obtained with the same cell-free virus prepara-
tion. Equal volumes of virus, serial dilutions of heat-
inactivated mouse serum and 1:4 diluted guinea pig
serum, as source of complement, were mixed and incu-
bated for 1 h at 34°C. To test complement-independent
antibodies, the heat-inactivated (56°C/30 min) guinea pig
serum was used in the mixtures. In the control mixtures,
the serum tested was replaced by medium. A volume of
0.3 ml of each mixture was inoculated on two 60-mm
Petri dishes with LEP cell monolayer at room tempera-
ture and 30 min later 5 ml of culture medium (E-MEM,
10% heat-inactivated newborn calf serum) was added.
After 10 days of incubation at 37°C, the medium was
removed and cells were stained (E-MEM, 1% calf serum,
0.05% neutral red) at room temperature for $1 h. Plaques
were counted immediately after removal of staining me-
dium. The neutralizing titer was expressed as the recip-
rocal of the highest serum dilution causing $50% plaque
number reduction in relation to control.
Skin test in guinea pigs
Groups of three to four outbred female guinea pigs
(BFA strain) weighing 225–250 g were injected with two
separate doses of 5.106 PFU of recombinant VV in 0.5 ml
BS given simultaneously intraperitoneally and subcuta-
eously in the back. Control animals received PBS only.
ne group of animals was injected subcutaneously with
.103 PFU of extracellular VZV-Oka. Skin tests were per-
formed 18 days after immunization. Skin test antigens
were prepared according to the modified method of Ka-
miya et al. (1977). In brief, the OKA strain of VZV was
used for preparation of skin-test antigen. Monolayers of
LEP cells with freshly changed medium EPL were inoc-
ulated with virus-infected cells at a ratio of one infected
cell to four uninfected cells. After incubation at 37°C for
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219IMMUNIZATION WITH VZV GLYCOPROTEINS48 h, the cells were washed three times with PBS and fed
with serum-free DMEM medium. The cultures were in-
cubated at 37°C for 5 h and again washed three times
with PBS. Cells were scraped off, suspended in PBS, and
the suspension was centrifuged at 600 g for 10 min. The
sediment was resuspended in PBS, sonicated in a Soni-
prep MSE (amplitude 12 mm) for 2 min and centrifuged at
000 g for 20 min. The supernatant was UV-irradiated for
0 min to inactivate infectious virus. Control antigen was
repared from noninfected cells by the same procedure.
he materials were kept at 265°C until used. Volumes of
0 ml of positive or control skin test antigens containing
60 mg of total protein were injected intradermally in
either flank of locally shaved animals. Cutaneous reac-
tion was measured 48 h after injection, and its size for
each animal was calculated using following formula:
Area 5 (long diameterVZV 3 short diameterVZV) 2 (long
iametercontrol 3 short diametercontrol). The data were sta-
tistically analysed using unpaired t test.
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